MedTrace Logo

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

NCT06113900 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-11-02

No results posted yet for this study

Summary

The aim of this study is to assess the safety and efficacy of SGLT2is among LN patients.

Conditions

Interventions

DRUG

Dapagliflozin 10mg Tab orally once daily

Sodium glucose co-transporter 2 inhibitors

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Howaida Al-Shennawi, Professor · Professor of internal medicine and Nephrology

  • Cherry Kamel, Professor · Professor of internal medicine and Nephrology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-12-01
Completion
2025-01-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06113900 on ClinicalTrials.gov